ARTICLE

FindCenter AddIcon

Well Woman Interview: Natalie Lyla Ginsberg

By Tonya Papanikolov

MAPS is a non-profit research and educational organization based in California that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Natalie’s work takes her around the world, from speaking to conservative medical professionals to representing MAPS at the United Nations Commission on Narcotic Drugs where passionate and diverse professionals gather to end the drug war.

Read on thewellwoman.co

FindCenter Post-Image

The Cost of Exclusion in Psychedelic Research

In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.

FindCenter AddIcon
FindCenter Post-Image

Psychedelic Psychotherapy Is Coming: Who Will Be Included?

A new study finds widespread exclusion of minorities in psychedelic research.

FindCenter AddIcon
FindCenter Post-Image

How Researchers and Advocates of Color Are Forging Their Own Paths in Psychedelic-Assisted Therapy

We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.

FindCenter AddIcon
FindCenter Post-Image

Study Finds Ketamine Can Help Patients Manage Depression and PTSD

Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.

FindCenter AddIcon
FindCenter Post-Image

Who Will Benefit From Psychedelic Medicine?

These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

FindCenter AddIcon
FindCenter Post-Image

Psychedelics and Race: A Profile of Dr. Monnica T. Williams

The exuberant “renaissance” of studies researching psychedelic-assisted psychotherapy in the past twenty years has not sufficiently included the enrollment of racially diverse participants, a problem that psychedelic science and clinical research shares with mainstream psychiatry

FindCenter AddIcon
FindCenter Post-Image

VA Rejects Cannabis Research as Veterans Plead for Medical Pot

The VA continues to deny cannabis recommendations to veterans in 36 states that allow medical marijuana.

FindCenter AddIcon
FindCenter Post-Image

What Are the Health Benefits and Risks of Marijuana?

Cannabis — also referred to as marijuana — is a psychoactive drug that many people use for recreational purposes and its purported medicinal benefits. But what does recent research say about it? Do the risks trump the benefits?

FindCenter AddIcon
FindCenter Post-Image

A Psychedelic Drug Passes Big Test for PTSD Treatment

In an important step toward medical approval, MDMA, the illegal drug popularly known as Ecstasy or Molly, was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy.

FindCenter AddIcon
FindCenter Post-Image

Repeated Ketamine Infusions Reduce PTSD Symptom Severity

Repeated intravenous (IV) ketamine infusions significantly reduce symptom severity in individuals with chronic post-traumatic stress disorder (PTSD) and the improvement is rapid and maintained for several weeks afterwards, according to a new study.

FindCenter AddIcon

EXPLORE TOPIC

Psychedelic Research